These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34349063)

  • 21. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab].
    Shutov SA; Zozulya NI; Novikov VA; Shutova NA; Glebova AI; Kitsenko EA
    Khirurgiia (Mosk); 2023; (5):72-83. PubMed ID: 37186654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
    Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.
    Valke LLFG; Bukkems LH; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Mathôt RAA; van Heerde WL; Schols SEM
    J Thromb Haemost; 2020 Dec; 18(12):3222-3231. PubMed ID: 32979031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies.
    Slatter DA; Percy CL; Allen-Redpath K; Gajsiewicz JM; Brooks NJ; Clayton A; Tyrrell VJ; Rosas M; Lauder SN; Watson A; Dul M; Garcia-Diaz Y; Aldrovandi M; Heurich M; Hall J; Morrissey JH; Lacroix-Desmazes S; Delignat S; Jenkins PV; Collins PW; O'Donnell VB
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
    Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
    Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition.
    Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
    Haemophilia; 2021 Mar; 27(2):e194-e203. PubMed ID: 33555083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maturation of coagulation factor IX during Xase formation as deduced using factor VIII-derived peptides.
    Fang H; Zögg T; Brandstetter H
    FEBS Open Bio; 2019 Aug; 9(8):1370-1378. PubMed ID: 31077577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
    Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
    Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
    Samuelson Bannow B; Recht M; Négrier C; Hermans C; Berntorp E; Eichler H; Mancuso ME; Klamroth R; O'Hara J; Santagostino E; Matsushita T; Kessler C
    Blood Rev; 2019 May; 35():43-50. PubMed ID: 30922616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emicizumab for the treatment of acquired hemophilia A.
    Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
    Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
    Kitazawa T; Igawa T; Sampei Z; Muto A; Kojima T; Soeda T; Yoshihashi K; Okuyama-Nishida Y; Saito H; Tsunoda H; Suzuki T; Adachi H; Miyazaki T; Ishii S; Kamata-Sakurai M; Iida T; Harada A; Esaki K; Funaki M; Moriyama C; Tanaka E; Kikuchi Y; Wakabayashi T; Wada M; Goto M; Toyoda T; Ueyama A; Suzuki S; Haraya K; Tachibana T; Kawabe Y; Shima M; Yoshioka A; Hattori K
    Nat Med; 2012 Oct; 18(10):1570-4. PubMed ID: 23023498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
    Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
    Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.
    Hamedani NS; Oldenburg J; Pötzsch B; Müller J
    PLoS One; 2022; 17(7):e0271330. PubMed ID: 35834493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.